Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q13642: Variant p.Cys153Arg

Four and a half LIM domains protein 1
Gene: FHL1
Feedback?
Variant information Variant position: help 153 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Cysteine (C) to Arginine (R) at position 153 (C153R, p.Cys153Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (C) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In RBMX1B. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 153 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 323 The length of the canonical sequence.
Location on the sequence: help KQVIGTGSFFPKGEDFYCVT C HETKFAKHCVKCNKAITSGG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         KQVI----------GTGSFFPKGEDFYCVTCHETKFAKHCV-------------------------------------------------KCNKAITSGG

Mouse                         KQVI----------GTGSFFPKGEDFYCVTCHETKFAKHCV

Rat                           KQVI----------GTGSFFPKGEDFYCVTCHETKFAKHCV

Baker's yeast                 NKSF----RKVSKEGKGWLWGLDEEY--IAERERQKKKQSE

Fission yeast                 NKAFIRIPRRQNEPGKGSFWMLDPSY--IDQFEGNFFRRTK

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 323 Four and a half LIM domains protein 1
Domain 101 – 153 LIM zinc-binding 2
Helix 151 – 157



Literature citations
Proteomic identification of FHL1 as the protein mutated in human reducing body myopathy.
Schessl J.; Zou Y.; McGrath M.J.; Cowling B.S.; Maiti B.; Chin S.S.; Sewry C.; Battini R.; Hu Y.; Cottle D.L.; Rosenblatt M.; Spruce L.; Ganguly A.; Kirschner J.; Judkins A.R.; Golden J.A.; Goebel H.-H.; Muntoni F.; Flanigan K.M.; Mitchell C.A.; Boennemann C.G.;
J. Clin. Invest. 118:904-912(2008)
Cited for: INVOLVEMENT IN RBMX1A; INVOLVEMENT IN RBMX1B; VARIANTS RBMX1A TYR-123 AND PHE-132; VARIANTS RBMX1B TYR-153 AND ARG-153; Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1.
Schessl J.; Taratuto A.L.; Sewry C.; Battini R.; Chin S.S.; Maiti B.; Dubrovsky A.L.; Erro M.G.; Espada G.; Robertella M.; Saccoliti M.; Olmos P.; Bridges L.R.; Standring P.; Hu Y.; Zou Y.; Swoboda K.J.; Scavina M.; Goebel H.H.; Mitchell C.A.; Flanigan K.M.; Muntoni F.; Boennemann C.G.;
Brain 132:452-464(2009)
Cited for: VARIANTS RBMX1A GLN-123; LEU-123; TYR-123 AND PHE-132; VARIANTS RBMX1B ARG-153 AND TYR-153;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.